Abiopharma

🔍 Jackson Blair Curtis (Director)

Company: Alkermes plc. (ALKS)

Report Date: 2026-08-05

Detailed Transactions and Holdings:

• Acquired 93,229 shares of Employee Stock Option (Right to Buy) at $49.61 per share (Derivative)
  Date: 2026-08-05 | Code: A | Expires: 2036-08-05 | equity_swap_involved: 0 | shares_owned_after: 93,229.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 124,305 shares of Employee Stock Option (Right to Buy) at $49.61 per share (Derivative)
  Date: 2026-08-05 | Code: A | Expires: 2036-08-05 | equity_swap_involved: 0 | shares_owned_after: 124,305.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: This award was granted in connection with the reporting person's appointment as President and Chief Executive Officer.
• F2: Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 8/5/2027.
• F3: Shares underlying the stock option shall vest and become exercisable, if at all, in two tranches based upon the closing price of an ordinary share of Alkermes plc, as reported by the Nasdaq Global Select Market or another national securities exchange on which Alkermes plc's ordinary shares are listed, trading at certain pre-specified levels for 30 consecutive trading days, subject in each case to the reporting person's completion of two years of continuous service (or less, in the event of a change in control) in the role of President and Chief Executive Officer. This award expires ten years from the date of grant.